rifalazil

rifalazil

Infectious disease A rifampin derivative effective against TB, which has a longer T1⁄2 and intracellular concentrations, allowing shorter treatment, fewer doses, better Pt compliance. See Rifampin.
Mentioned in ?
References in periodicals archive ?
A parte de estos medicamentos, en los ultimos anos se ha venido estudiando la posibilidad de nuevos medicamentos para el tratamiento de la infeccion por CD (25) entre los que se incluyen fidaxomicina, nitazoxanida, rifaximine, ramoplanine, tigeciclina, rifalazil, probioticos e inmunoterapia pasiva.
Rifalazil is currently in clinical development with Phase I and Phase II trials underway or planned for several indications.
This brings the total number to 15 US patents covering rifalazil and its use for treating bacterial infections.
ActivBiotics exclusively licensed rifalazil from Kaneka Corporation (Japan).
Rifalazil and rifaximin were the most potent agents against the strains tested, but resistance to both agents in some isolates was observed.
10:00 am - 11:30 am: E-1439/164 In Vitro Activity of Ramoplanin, Rifalazil, Rifaximin, Metronidazole, and Vancomycin against 110 Unique Toxigenic Clostridium difficile Clinical Isolates (poster)
In October, DepoMed announced a memorandum of understanding to develop a controlled-release oral tablet to deliver ActivBiotics' broad-spectrum lead compound, rifalazil, to the gastrointestinal tract, targeting H.
The product will be a controlled-release oral tablet which delivers ActivBiotics' broad-spectrum lead compound, rifalazil, to the stomach and gastrointestinal tract.
AMEX:DMI) today announced a memorandum of understanding under which DepoMed will develop a controlled-release oral tablet which delivers ActivBiotics' broad spectrum lead compound, rifalazil, to the gastrointestinal tract.
ActivBiotics' CEO, stated, "Given the unique potency, distribution, and pharmacokinetic properties of our lead compound, rifalazil, this is a unique opportunity to partner with DepoMed's experienced team and develop a new improved product, Rifalazil GR, for gastrointestinal diseases.